Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles
Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome …

The recent advancements in the knowledge of lysosomal biology and function have
translated into an improved understanding of the pathophysiology of …

Heparan sulfate proteoglycans (HSPGs) are complex carbohydrate-modified proteins
ubiquitously expressed on cell surfaces, extracellular matrix and basement membrane of …

Lysosomes play a central role in cellular homeostasis and alterations in this compartment
associate with many diseases. The most studied example is that of lysosomal storage …

Lysosomal storage diseases (LSDs) comprise a group of inherited monogenic disorders
characterized by lysosomal dysfunctions due to undegraded substrate accumulation. They …

In 2019, the Nosology Committee of the International Skeletal Dysplasia Society provided an
updated version of the Nosology and Classification of Genetic Skeletal Disorders. This is a …

Hypoxia is one of the major threats to the aquaculture sector resulting in substantial
economic losses to the fish farmers. Thus, tolerance to hypoxia is of high economic interest …

Multiple complex intracellular cascades contributing to Hunter syndrome (
mucopolysaccharidosis type II) pathogenesis have been recognized and documented in the …

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder based on a mutation
in the IDS gene that encodes iduronate 2-sulphatase. As a result, there is an accumulation …

Mucopolysaccharidosis (MPS) is a group of inherited conditions involving metabolic
dysfunction. Lysosomal enzyme deficiency leads to the accumulation of glycosaminoglycan …